Para acceder a los documentos con el texto completo, por favor, siga el siguiente enlace: http://hdl.handle.net/2445/108575
dc.contributor | Universitat de Barcelona |
---|---|
dc.contributor.author | Ampudia-Blasco, Francisco Javier |
dc.contributor.author | Romera, Irene |
dc.contributor.author | Ariño, Bernat |
dc.contributor.author | Gomis, Ramon, 1946- |
dc.date | 2017-03-17T14:48:07Z |
dc.date | 2017-03-17T14:48:07Z |
dc.date | 2017-01-13 |
dc.date | 2017-03-17T14:48:07Z |
dc.identifier.citation | 1178-7074 |
dc.identifier.citation | 669654 |
dc.identifier.uri | http://hdl.handle.net/2445/108575 |
dc.format | 4 p. |
dc.format | application/pdf |
dc.language.iso | eng |
dc.relation | https://doi.org/10.2147/IJGM.S115566 |
dc.relation | International Journal of General Medicine, 2017, vol. 10, p. 23-26 |
dc.relation | https://doi.org/10.2147/IJGM.S115566 |
dc.rights | cc-by-nc (c) Ampudia-Blasco, Francisco Javier, 2017 |
dc.rights | info:eu-repo/semantics/openAccess |
dc.rights | http://creativecommons.org/licenses/by-nc/3.0/es/ |
dc.subject | Malalties cardiovasculars |
dc.subject | Diabetis |
dc.subject | Glucosa |
dc.subject | Cardiovascular diseases |
dc.subject | Diabetes |
dc.subject | Glucose |
dc.title | Following the results of the EMPA-REG OUTCOME trial with Empagliflozin, is it possible to speak of a class effect? |
dc.type | info:eu-repo/semantics/article |
dc.type | info:eu-repo/semantics/publishedVersion |
dc.description.abstract |